CTRI/2018/03/012274招募中2 期
Phase IIb/III study to determine efficacy of Curcumin and Metformin to reduce the incidence of second primary tumors of aero-digestive tract in patients with history of head and neck squamous cell carcinoma
ational Cancer Grid0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.History of head and neck squamous cell carcinoma excluding that of paranasal sinuses and nasopharynx with stage no higher than T1/2/3, N0/1, M0 who were treated with curative-intent within three to twelve months prior to accrual for the study.
- •2.All patients must be free of disease and recovered from initial treatment related complications.
- •3.All patients must have undergone curative intent treatment within three to twelve months of randomization.
- •4.All patients must have had CT scan of head and neck and chest at base line (within six months prior to enrollment)
- •5.Patients must be at least 18 years of age.
- •6.All patients must sign an informed consent before enrolling in study.
- •7.Patients must be able and willing to return to the clinic at appropriately scheduled intervals.
- •8.Pre-menopausal and peri-menopausal women must be using adequate birth control methods and have a negative pregnancy test prior to entry.
- •9.Patients who have not taken supplements of retinol, beta carotene, vitamin E, Selenium or other chemopreventive therapy at least three months prior to the baseline visit and all toxicities have been fully resolved.
- •10.Karnofsky Performance Score above 80.
- •11.The subject meets the following laboratory eligibility criteria during a time not to exceed 4 weeks prior to randomization.
- •a.Hemoglobin level above or equal 10gm percentage.
- •b.WBC count greater than 3,000 mm3.
- •c.Platelets count greater than 100,000 m3.
- •d.Total bilirubin, AST (SGOT) and ALT (SGPT)less than or equal to 1.5 x ULN.
- •e.Serum creatinine less than or equal to 2 x ULN
- •12.The subject is willing and able to fully participate for the duration of the study.
- •13.If applicable, the subject has been counseled on smoking cessation and alcoholism.
排除标准
- •1.Female patients who are pregnant or lactating.
- •2.Presence of any active malignant diseases.
- •3.Unknown primary tumor of head and neck.
- •4.Patients with salivary gland malignancies
- •5.Subjects with unstable cardiac and renal diseases
- •6.Subject who are diagnosed and under treatment for diabetes.
- •7.Subjects who are greater than 80 years in age.
- •8.The subject will need concurrent chemotherapy, radiotherapy, hormonal (other than HRT for menopause), or immunotherapy during the time of study.
- •9.The subject has a history of hypersensitivity to Metformin.
- •10.Subject with estimated Glomerular Filtration Rate less than 40 mL/min.
- •11.The subject is, in the opinion of the Institutional Principal Investigator, not an appropriate candidate for study participation.
- •12.The subject participated in the study previously and was withdrawn
- •13.The subject has not recovered from the acute toxic effects of chemotherapy, immunotherapy, hormonal therapy, or radiation therapy.
研究者
相似试验
已完成
不适用
Effect of a a novel curcumin-galactomannoside complex (CGM)delivery syste on Improvement of liver function markers in chronic alcoholic patients.CTRI/2018/03/012385Akay Flavours And Aromatics Pvt Ltd48
已完成
2 期
A phase II study to investigate the efficacy of neoadjuvant erlotinib in patients with clinical stage I/II non-small cell lung cancer (NSCLC)early stage lung cancernon-small cell lung cancer stage I/II10038666NL-OMON29708Antoni van Leeuwenhoek Ziekenhuis55
已完成
2 期
Phase II/III study to investigate the efficacy of 5-aminolaevulinic acid (ALA)-based photodynamic therapy in the treatment of Bowen's disease, actinic keratoses and study the effect of dose fractionation for superficial basal cell carcinomasBowen's diseaseCarcinoma in situ of skinCancerISRCTN93864182Department of Health (UK)
尚未招募
不适用
Efficiency of curcuminoids as an adjuvant treatment in plaque type psoriasisplaque type psoriasisTCTR20180419003Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand80
进行中（未招募）
不适用
Ensayo Clínico Fase II para evaluar la eficacia de la combinación con sorafenib + dacarbacina (DTIC) en pacientes con melanoma metastásico (estadío IV) (estudio SORAFENIB-DTIC). - SORAFENIB-DTICMELANOMA METASTASICOEUCTR2005-005138-11-ESDr. JOSE LUIS GONZALEZ LARRIBA